New combination of Sovaldi + GS 5816 success in Hepatitis C study - Gilead
In an abstract released ahead of European Association for the Study of the Liver meeting, Gilead Sciences Inc. said once-daily HCV drug Sovaldi (sofosbuvir) plus GS-5816 for 12 weeks led to a sustained virologic response (SVR) four weeks after the end of treatment in 86-100% of HCV patients in a Phase II trial.
The trial enrolled 154 treatment-na�ve patients with HCV genotypes 1-6 infection without cirrhosis. Gilead is scheduled to present data from the trial at the European Association for the Study of the Liver meeting next month. GS-5816 is an oral pan-genotypic HCV NS5A inhibitor, and Sovaldi is a nucleotide analog HCV NS5B polymerase inhibitor.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma